Repeated systemic thrombolysis after early recurrent stroke: always hazardous?

[no abstract available

Head drop in progressive supranuclear palsy: An unusual association with amyotrophic lateral sclerosis.

no abstract availabl

SemEval-2018 Task 9: hypernym discovery

Comunicació presentada al 12th International Workshop on Semantic Evaluation (SemEval-2018), celebrat els dies 5 i 6 de juny de 2018 a Nova Orleans, EUA.This paper describes the SemEval 2018 Shared Task on Hypernym Discovery. We put forward this task as a complementary benchmark for modeling hypernymy, a problem which has traditionally been cast as a binary classification task, taking a pair of candidate words as input. Instead, our reformulated task is defined as follows: given an input term, retrieve (or discover) its suitable hypernyms from a target corpus. We proposed five different subtasks covering three languages (English, Spanish, and Italian), and two specific domains of knowledge in English (Medical and Music). Participants were allowed to compete in any or all of the subtasks. Overall, a total of 11 teams participated, with a total of 39 different systems submitted through all subtasks. Data, results and further information about the task can be found at https://competitions. codalab.org/competitions/17119.The authors gratefully acknowledge the economic support in the construction of the datasets from the Maria de Maeztu-UPF Grant provided to Horacio Saggion, Luis Espinosa-Anke and Sergio Oramas; Google Research through the Google Doctoral Fellowship in Natural Language Processing to Jose Camacho-Collados; and Bar-Ilan University through Vered Shwartz. This work is partially supported by the TUNER project (TIN2015- 65308-C5-5-R, MINECO/FEDER, UE), Spanish Ministry of Economy and Competitiveness

The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism

Olfactory impairment has been reported in drug-induced parkinsonism (DIP), but the relationship between dopaminergic dysfunction and smell deficits in DIP patients has not been characterized. To this end, we studied 16 DIP patients and 13 patients affected by Parkinson's disease (PD) using the "Sniffin' Sticks" test and [(123)I] FP-CIT SPECT (single-photon emission computed tomography). DIP patients were divided based on normal (n = 9) and abnormal (n = 7) putamen dopamine transporter binding. Nineteen healthy age- and sex-matched subjects served as controls of smell function. Patients with DIP and pathological putamen uptake had abnormal olfactory function. In this group of patients, olfactory TDI scores (odor threshold, discrimination and identification) correlated significantly with putamen uptake values, as observed in PD patients. By contrast, DIP patients with normal putamen uptake showed odor functions-with the exception of the threshold subtest-similar to control subjects. In this group of patients, no significant correlation was observed between olfactory TDI scores and putamen uptake values. The results of our study suggest that the presence of smell deficits in DIP patients might be more associated with dopaminergic loss rather than with a drug-mediated dopamine receptor blockade. These preliminary results might have prognostic and therapeutic implications, as abnormalities in these individuals may be suggestive of an underlying PD-like neurodegenerative process

Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study

Similarly to subjects with degenerative parkinsonism, (123)I-FP-CIT SPECT has been reported either normal or abnormal in patients with drug-induced parkinsonism (DIP), challenging the notion that parkinsonism might be entirely due to post-synaptic D2-receptors blockade by antipsychotic drugs. In a previous multicenter cross-sectional study conducted on a large sample of patients with schizophrenia, we identified 97 patients who developed parkinsonism with a similar bi-modal distribution of DAT-SPECT. In this longitudinal study, we reported clinical and imaging features associated with progression of motor disability over 2-year follow-up in 60 out of those 97 patients with schizophrenia and parkinsonism who underwent (123)I-FP-CIT SPECT at baseline evaluation (normal SPECT=33; abnormal SPECT=27). As second end-point, chronic response to levodopa over a 3-month period was tested in a subgroup of subjects. Motor Unified Parkinson's Disease Rating Scale (UPDRS) at follow-up significantly increased in patients with abnormal SPECT. Specifically, a 6-point worsening was demonstrated in 18.5% of the subjects with abnormal SPECT and in none of the subjects with normal SPECT. Levodopa treatment improved motor UPDRS only in the group with abnormal SPECT. After adjustment for possible confounders, linear regression analysis demonstrated that abnormal SPECT findings at baseline were the only predictor of motor disability progression and of better outcome of levodopa treatment. Our results support the notion that a degenerative disease might underlie parkinsonism in a minority of schizophrenic patients chronically exposed to antipsychotics. Functional imaging of the dopamine transporter can be helpful to select this patient sub-group that might benefit from levodopa therapy